SALT LAKE CITY, Jan. 4, 2011 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company developing diagnostic tests for early prediction of preterm birth and other pregnancy complications, today announced that it raised $1.4 million in Series A-1 financing. Sera is currently developing a simple blood test that measures proprietary biomarkers that are highly predictive of preterm birth risk.
